ArticleThe oncologist2021

First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.

Jennifer E Amengual et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.